You are here:
ethinylestradiol with drosperinone (Yasmin)
Advice
following a resubmission
drospirenone/ethinylestradiol (Yasmin®) is not recommended for use within NHS Scotland.
Indication under review: oral contraception.
Drospirenone/ethinylestradiol has been shown to have similar contraceptive effectiveness to other combined oral contraceptives in routine use, with no significant differences in adverse event profile.
The manufacturer did not present a sufficiently robust economic case to gain acceptance by SMC.
Drug Details
| Drug Name: | ethinylestradiol with drosperinone (Yasmin) |
|---|---|
| SMC Drug ID: | 23/03 |
| Manufacturer: | Bayer plc/Bayer Schering Pharma |
| Indication: | Oral contraception |
| BNF Category: | |
| Sub Category: | 7.3 Contraceptives |
| Submission Type: | Resubmission |
| Status: | Not Recommended |
| Date Advice Published: | 11 April 2011 |
Archived Advice
| Drospirenone ethinylestradiol (Yasmin®) | Full submission | 7 March 2003 |